CN108433106A - A kind of Oxygen-deficient endurance fructose powder (liquid) composition - Google Patents
A kind of Oxygen-deficient endurance fructose powder (liquid) composition Download PDFInfo
- Publication number
- CN108433106A CN108433106A CN201711083908.3A CN201711083908A CN108433106A CN 108433106 A CN108433106 A CN 108433106A CN 201711083908 A CN201711083908 A CN 201711083908A CN 108433106 A CN108433106 A CN 108433106A
- Authority
- CN
- China
- Prior art keywords
- oxygen
- endurance
- deficient
- blood
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052760 oxygen Inorganic materials 0.000 title claims description 74
- 239000001301 oxygen Substances 0.000 title claims description 74
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title claims description 73
- 239000000203 mixture Substances 0.000 title claims description 31
- 239000000843 powder Substances 0.000 title claims description 30
- 239000007788 liquid Substances 0.000 title claims description 23
- 229930091371 Fructose Natural products 0.000 title claims description 22
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 title claims description 22
- 239000005715 Fructose Substances 0.000 title claims description 22
- 230000002950 deficient Effects 0.000 title claims description 16
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 60
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims abstract description 40
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 34
- 229960003080 taurine Drugs 0.000 claims abstract description 30
- 240000005373 Panax quinquefolius Species 0.000 claims abstract description 26
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 25
- 239000000284 extract Substances 0.000 claims abstract description 18
- 239000002211 L-ascorbic acid Substances 0.000 claims abstract description 10
- 235000000069 L-ascorbic acid Nutrition 0.000 claims abstract description 10
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- 239000003795 chemical substances by application Substances 0.000 claims description 24
- 238000002360 preparation method Methods 0.000 claims description 24
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 23
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 20
- 229930064664 L-arginine Natural products 0.000 claims description 20
- 235000014852 L-arginine Nutrition 0.000 claims description 20
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 18
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- 229960004203 carnitine Drugs 0.000 claims description 13
- 239000011777 magnesium Substances 0.000 claims description 13
- 229910052749 magnesium Inorganic materials 0.000 claims description 13
- 239000007787 solid Substances 0.000 claims description 12
- 239000002552 dosage form Substances 0.000 claims description 11
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 10
- 229960001518 levocarnitine Drugs 0.000 claims description 10
- 239000004302 potassium sorbate Substances 0.000 claims description 10
- 235000010241 potassium sorbate Nutrition 0.000 claims description 10
- 229940069338 potassium sorbate Drugs 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 10
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 9
- VDTNNGKXZGSZIP-UHFFFAOYSA-N carbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 VDTNNGKXZGSZIP-UHFFFAOYSA-N 0.000 claims description 9
- 239000013078 crystal Substances 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 235000012907 honey Nutrition 0.000 claims description 8
- 230000001954 sterilising effect Effects 0.000 claims description 8
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 7
- 229930003268 Vitamin C Natural products 0.000 claims description 7
- 238000003860 storage Methods 0.000 claims description 7
- 239000011718 vitamin C Substances 0.000 claims description 7
- 235000019154 vitamin C Nutrition 0.000 claims description 7
- 238000004659 sterilization and disinfection Methods 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 5
- 229940100688 oral solution Drugs 0.000 claims description 5
- 239000008367 deionised water Substances 0.000 claims description 4
- 229910021641 deionized water Inorganic materials 0.000 claims description 4
- 210000004907 gland Anatomy 0.000 claims description 4
- 238000007873 sieving Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 239000007909 solid dosage form Substances 0.000 claims description 3
- 240000004307 Citrus medica Species 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 238000007789 sealing Methods 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- 238000011049 filling Methods 0.000 claims 1
- 238000012432 intermediate storage Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 44
- 206010021143 Hypoxia Diseases 0.000 abstract description 40
- 238000012360 testing method Methods 0.000 abstract description 34
- 206010002660 Anoxia Diseases 0.000 abstract description 14
- 235000013305 food Nutrition 0.000 abstract description 14
- 230000036541 health Effects 0.000 abstract description 14
- 241000976983 Anoxia Species 0.000 abstract description 13
- 230000007953 anoxia Effects 0.000 abstract description 13
- 230000033001 locomotion Effects 0.000 abstract description 10
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 abstract description 4
- 239000000470 constituent Substances 0.000 abstract description 4
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 abstract description 3
- 229920000377 Sinistrin Polymers 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 239000004475 Arginine Substances 0.000 abstract description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 54
- 239000008280 blood Substances 0.000 description 38
- 210000004369 blood Anatomy 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 37
- 230000006870 function Effects 0.000 description 27
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 26
- 239000003814 drug Substances 0.000 description 26
- 210000004072 lung Anatomy 0.000 description 26
- 239000000463 material Substances 0.000 description 22
- 238000002474 experimental method Methods 0.000 description 21
- 239000011734 sodium Substances 0.000 description 19
- 230000002685 pulmonary effect Effects 0.000 description 18
- 239000007789 gas Substances 0.000 description 17
- 230000001146 hypoxic effect Effects 0.000 description 17
- 229910001415 sodium ion Inorganic materials 0.000 description 17
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 16
- 229910052708 sodium Inorganic materials 0.000 description 16
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 15
- 210000000170 cell membrane Anatomy 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 15
- 230000002792 vascular Effects 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 14
- 108090000790 Enzymes Proteins 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 238000010171 animal model Methods 0.000 description 14
- 206010016256 fatigue Diseases 0.000 description 14
- 230000003647 oxidation Effects 0.000 description 13
- 238000007254 oxidation reaction Methods 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 206010062717 Increased upper airway secretion Diseases 0.000 description 11
- 210000004204 blood vessel Anatomy 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 11
- 208000026435 phlegm Diseases 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 230000034994 death Effects 0.000 description 10
- 210000003470 mitochondria Anatomy 0.000 description 9
- 210000000056 organ Anatomy 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 238000003304 gavage Methods 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 230000002438 mitochondrial effect Effects 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 8
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 7
- 206010030113 Oedema Diseases 0.000 description 7
- 230000002929 anti-fatigue Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- 230000002708 enhancing effect Effects 0.000 description 7
- 239000000686 essence Substances 0.000 description 7
- 235000013402 health food Nutrition 0.000 description 7
- 230000007954 hypoxia Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 229910001425 magnesium ion Inorganic materials 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 7
- 230000001575 pathological effect Effects 0.000 description 7
- 210000001147 pulmonary artery Anatomy 0.000 description 7
- 239000013558 reference substance Substances 0.000 description 7
- 230000009182 swimming Effects 0.000 description 7
- 102400000686 Endothelin-1 Human genes 0.000 description 6
- 101800004490 Endothelin-1 Proteins 0.000 description 6
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 6
- 125000002252 acyl group Chemical group 0.000 description 6
- 210000001367 artery Anatomy 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 229910001424 calcium ion Inorganic materials 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 230000004087 circulation Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 238000004321 preservation Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- NWCHELUCVWSRRS-SECBINFHSA-N (2r)-2-hydroxy-2-phenylpropanoic acid Chemical class OC(=O)[C@@](O)(C)C1=CC=CC=C1 NWCHELUCVWSRRS-SECBINFHSA-N 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 239000010839 body fluid Substances 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 229910002092 carbon dioxide Inorganic materials 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 210000004165 myocardium Anatomy 0.000 description 5
- 230000003204 osmotic effect Effects 0.000 description 5
- -1 phosphate organic compound Chemical class 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 208000002815 pulmonary hypertension Diseases 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000029058 respiratory gaseous exchange Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000032258 transport Effects 0.000 description 5
- 210000001835 viscera Anatomy 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 241000370738 Chlorion Species 0.000 description 4
- 208000000112 Myalgia Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 208000005374 Poisoning Diseases 0.000 description 4
- 102000005393 Sodium-Potassium-Exchanging ATPase Human genes 0.000 description 4
- 108010006431 Sodium-Potassium-Exchanging ATPase Proteins 0.000 description 4
- MIJPAVRNWPDMOR-UHFFFAOYSA-N [2-(1,2-dihydroxyethyl)-3-hydroxy-5-oxo-2h-furan-4-yl] dihydrogen phosphate Chemical compound OCC(O)C1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000003288 anthiarrhythmic effect Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 4
- 230000003727 cerebral blood flow Effects 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 239000009524 danshen dripping Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 238000007726 management method Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 230000036284 oxygen consumption Effects 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 231100000572 poisoning Toxicity 0.000 description 4
- 230000000607 poisoning effect Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000004088 pulmonary circulation Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- 206010001497 Agitation Diseases 0.000 description 3
- 208000012639 Balance disease Diseases 0.000 description 3
- 206010048962 Brain oedema Diseases 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 101710088194 Dehydrogenase Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 3
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 3
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 3
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 3
- 238000011047 acute toxicity test Methods 0.000 description 3
- 210000004958 brain cell Anatomy 0.000 description 3
- 208000006752 brain edema Diseases 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 230000005779 cell damage Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 229910001414 potassium ion Inorganic materials 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000007634 remodeling Methods 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 235000017709 saponins Nutrition 0.000 description 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 231100000820 toxicity test Toxicity 0.000 description 3
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010052804 Drug tolerance Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 235000016623 Fragaria vesca Nutrition 0.000 description 2
- 240000009088 Fragaria x ananassa Species 0.000 description 2
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- 208000002740 Muscle Rigidity Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 2
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 238000003255 drug test Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000007938 effervescent tablet Substances 0.000 description 2
- 238000004146 energy storage Methods 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 150000002187 fatty acyl carnitines Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000026781 habituation Effects 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 210000001700 mitochondrial membrane Anatomy 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 208000013465 muscle pain Diseases 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 210000000107 myocyte Anatomy 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000007830 nerve conduction Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 238000013439 planning Methods 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 244000132619 red sage Species 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 235000011083 sodium citrates Nutrition 0.000 description 2
- HUAUNKAZQWMVFY-UHFFFAOYSA-M sodium;oxocalcium;hydroxide Chemical compound [OH-].[Na+].[Ca]=O HUAUNKAZQWMVFY-UHFFFAOYSA-M 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 2
- 230000002227 vasoactive effect Effects 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- NAVWVHRQSDHCHD-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;potassium Chemical compound [K].OC(=O)CC(O)(C(O)=O)CC(O)=O NAVWVHRQSDHCHD-UHFFFAOYSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 240000005250 Chrysanthemum indicum Species 0.000 description 1
- 244000241235 Citrullus lanatus Species 0.000 description 1
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 1
- 244000089742 Citrus aurantifolia Species 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- YTBSYETUWUMLBZ-UHFFFAOYSA-N D-Erythrose Natural products OCC(O)C(O)C=O YTBSYETUWUMLBZ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- YTBSYETUWUMLBZ-IUYQGCFVSA-N D-erythrose Chemical compound OC[C@@H](O)[C@@H](O)C=O YTBSYETUWUMLBZ-IUYQGCFVSA-N 0.000 description 1
- 208000018672 Dilatation Diseases 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 206010056474 Erythrosis Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 208000035202 High altitude pulmonary edema Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010049976 Impatience Diseases 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- XINCECQTMHSORG-UHFFFAOYSA-N Isoamyl isovalerate Chemical compound CC(C)CCOC(=O)CC(C)C XINCECQTMHSORG-UHFFFAOYSA-N 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 239000004425 Makrolon Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000005085 Meconium Aspiration Syndrome Diseases 0.000 description 1
- 241000581835 Monodora junodii Species 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-L NADH(2-) Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-L 0.000 description 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241001165494 Rhodiola Species 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000008445 altitude sickness Diseases 0.000 description 1
- 208000033571 alveolar capillary dysplasia with misalignment of pulmonary veins Diseases 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000000476 body water Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000000739 chaotic effect Effects 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000009989 contractile response Effects 0.000 description 1
- 230000001595 contractor effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 230000005574 cross-species transmission Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000005518 electrochemistry Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000001097 facial muscle Anatomy 0.000 description 1
- 125000001924 fatty-acyl group Chemical group 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000021393 food security Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 229940087603 grape seed extract Drugs 0.000 description 1
- 235000002532 grape seed extract Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000005096 hematological system Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 201000009939 hypertensive encephalopathy Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000008696 hypoxemic pulmonary vasoconstriction Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000002977 intracellular fluid Anatomy 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 230000020958 lipid digestion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000006677 mitochondrial metabolism Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 208000015001 muscle soreness Diseases 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000021401 pellet diet Nutrition 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 208000004594 persistent fetal circulation syndrome Diseases 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- NHDHVHZZCFYRSB-UHFFFAOYSA-N pyriproxyfen Chemical compound C=1C=CC=NC=1OC(C)COC(C=C1)=CC=C1OC1=CC=CC=C1 NHDHVHZZCFYRSB-UHFFFAOYSA-N 0.000 description 1
- 229940076788 pyruvate Drugs 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000002310 reflectometry Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008700 sympathetic activation Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000001717 vitis vinifera seed extract Substances 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
- A23L33/26—Polyol polyesters, e.g. sucrose polyesters; Synthetic sugar polymers, e.g. polydextrose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to field of health care food; more particularly to by active constituent D ribose, L arginine, taurine, American Ginseng medicinal extract, mono- carnitines of L, L-Ascorbic Acid L-O-Phosphate, polyfructosan and corrigent etc. at the health-care food being grouped as; rational prescription efficient combination ratio is selected by testing sieve; so that prescription effect generates synergistic effect; to effectively play the fatigue proof health-care effect of anti anoxia; it helps inferior health person or regains the enough energy needed for vital movement into plateau person, restore the due vigor of body.
Description
Technical field
The present invention relates to a kind of Oxygen-deficient endurance fructose powder (liquid) compositions.
Background technology
Health food refers to having specific healthcare function or the food for the purpose of replenishing vitamins, minerals, is applicable in
In specific crowd, have and adjust body function, not for the purpose for the treatment of disease, human body is not generated it is any it is acute, it is subacute or
The food of person's chronic hazard.Health food is human medical as a kind of functional food between drug and ordinary food
The important component of public health work.With the arrival in big healthy epoch, health food industry will welcome unprecedented development machine
It meets.
Using this overall background as opportunity, to accelerate the paces of health food development, meet the health service need of consumers in general
It asks, we are comprehensive to conclude prescription rule on the basis of the forefathers to different times study, and are exploitation with resist oxygen lack healthcare function
It is directed toward, former achievements is excavated, conclude, summarize and are distilled, in conjunction with nutrient theory, theory of traditional Chinese medical science, cellular elements reason
By the analysis of, cyto-dynamics scheduling theory, recreated from completely new angle.
But the environment on plateau has the unexistent feature in plains region:
First, oxygen content is low in the air of highlands.Result of study is shown, in 4300 meters of eminences of height above sea level, oxygen pressure
Only the 58% of sea level.Therefore, although in the air on plateau, the content ratio of oxygen does not change, since plateau is whole
The absolute magnitude of body rarefaction of air, oxygen has been small very much, and therefore, people from Plain enters plateau can lead to hypobaric hypoxia symptom mostly.
Followed by highlands very cold.For root it was found that often increasing 150 meters of height above sea levels, temperature will decline 1 degree;
1000 meters are often increased, 6.5 degree of mercury dropped.Therefore, the temperature of highlands is colder than other areas of Same Latitude.
Moreover it is exactly that humidity in the air of highlands is low.Plateau air is not only thin, but also very dry, in air
Humidity is very low.Some researches show that people is daily 1.5 liters by breathing the moisture of discharge on plateau, the water being discharged by skin
It is divided into 2.3 liters, under normal circumstances (in the case of not perspiring), body water exclusion amount increases by 1 than plains region human body discharge rate
Times or more.
That the distinctive geographical conditions in highlands and natural environment are simply analyzed above, as air pressure is low, oxygen is forced down,
It is cold low with humidity, moreover be exactly big, solar radiation strong (ultraviolet light and ionising radiation) of wind etc., these climatic characteristics are to Plain people
Into after plateau, it will a series of influence of physiological functions occurs, it is most important to be presented with:The anoxic of nervous centralis, breathing system
The various aspects symptom such as the anoxic of system, the anoxic of the circulatory system, anoxic of hematological system, people's habituation are referred to as altitude sickness.
In fact, human body anoxia is not only one type of high altitude anoxia.
Even in the people of plains region, also pathological hypoxic, physiological anoxic, motility anoxic and Environmental anoxic
Etc. different types of hypoxic conditions.
Pathological hypoxic refer to more suffer from respiratory disease, cardiovascular and cerebrovascular disease patient, due to from external world's intake oxygen and logical
The ability for crossing blood conveying oxygen declines, and causes body anoxic.Such as coronary heart disease, myocardial infarction, acute upper respiratory infection, chronic branch
Tracheitis includes chronic obstructive pulmonary disease etc..
Physiological anoxic.Refer to advancing age, each organ is physiological aging, directly contributes human body intake oxygen amount drop
It is low, it is reduced using the efficiency of oxygen, body is in the different chronic hypoxia state of degree.Lumen of vessels is narrow after people to old age, blood vessel
Elasticity reduces, and blood flow is reduced, and lung capacity declines, and fortune function is greatly reduced.The elderly takes in oxygen amount and reduces, and transports the energy of oxygen
Power reduces, and is declined using the efficiency of oxygen, and entire bodily tissue is in different degrees of anaerobic condition, and anoxic is exactly that the elderly is easy
The pathologic basis that brain, the heart, Liver and kidney function reduce occurs.
Motility anoxic, nervous muscle power and mental activity can cause body oxygen consumption to increase, due to internal oxygen demand urgency
Increase severely and add, merely by pulmonary respiration, is not enough to make up internal oxygen consumption, so that cell is in anaerobic environment, while adjoint
A large amount of lactic acid generate, this is why the reason of being easy to have a pain in the back after the mental labour of a large amount of physical sports or anxiety.
Environmental anoxic, under normal circumstances, the oxygen content in air are 20.9%.If being in an oxygen content to be less than
In 18% altitude environment, the oxygen of human body intake is insufficient, and the partial pressure of oxygen in blood is too low, and hemoglobin is in unsaturated shape
The cell of state, each section tissue will show corresponding hypoxic conditions due to occurring certain variation for hypoxgia.Generally
Come, every oxygen content is less than 20.9% environment, is all anaerobic environment.The even environment of slight hypoxia, gives birth to wherein for a long time
Living, work, can also bring health different degrees of damage.The rarefaction of air on plateau, high-altitude, although in plateau, high-altitude
In air, the ratio of oxygen is still 20.9%, but as height above sea level increases, and atmospheric density reduces, oxygen it is absolute
Amount is also corresponding to be reduced.
The whatsoever anoxic of type is all a kind of pessimal stimulation to body, influences the various metabolic functions of body, especially
The oxidative function of body is unbalance, and it is insufficient to eventually result in the supply of the major organs anoxic such as heart, brain, lung of body.
Therefore, the major function of anti-hypoxia health product is exactly to fight the anoxic of body, avoids the further development of lesion.When
Preceding related resist oxygen lack product in the market is many, is broadly divided into two major classes:Chinese medicine class and bio-extract class.
Bio-extract class type is more, such as grape seed extract, anthocyanidin, flavones, saponin etc..And vitamins is most
To be universal, vitamin can increase the oxygen carrying capacity of human body hemoglobin, improve blood oxygen saturation, have apparent enhancing to resist oxygen lack
Effect, meanwhile, vitamins also has the function of antioxidant, can effectively remove the free radical that body generates under anaerobic environment,
Improve Hypoxia toleration.
Second is that Chinese herbal medicine class.Such as rhodiola root, Radix Salviae Miltiorrhizae, ginseng, American Ginseng, matrimony vine, cordyceps sinensis, Radix Notoginseng Chinese medicine, including
Using Chinese medicine active compound as the health products of single preparations of ephedrine and compound preparation, all there is different degrees of resisting oxygen lack.
The present inventor summarizes after the achievement of conscientious extensive research China and foreign countries forefathers:
1, theory of traditional Chinese medical science thinks the long-term chronic anoxic of each cell of human body, organ, is only and endangers the true of human life and health
Positive " disease of danger ".Because theory of traditional Chinese medical science is to the importance of " gas " considerably beyond the theory of yin-yang and five elements (metal, wood, water, fire and earth), original theory of traditional Chinese medical science is
Using yin-yang and five elements as theoretical foundation as, human body is regarded to the entity of ' gas, shape, god '." knack cured the disease is to understand gas
Blood ", " vigour was both empty, must cannot reach in blood vessel, blood vessel must stop the interior stasis of blood without gas." if for the gas stasis of blood in internal organs, internal organs must acute disease
Here is life.Theory of traditional Chinese medical science illustrates ' anoxic ' symptom that modern medicine is thought, in Chinese medicine from the correlation of ' gas ' and ' blood ' of human body
In theory then be " qi being the governor of blood ", " blood being the material foundation of QI ", qi promoting blood production, gas can battalion blood vessels, the promoting circulation of blood of gas energy, QI can control blood,
The qi and blood dialectical relationship of blood can carry QI.The impetus of gas is the power of blood, and the effect of taking the photograph of consolidating of gas makes among blood vascular
It does not spill over outside arteries and veins.Blood again can be angry simultaneously, and blood constantly provides nutrition support for the generation of gas, and gas is present in blood, depends on blood
Delivery and reach whole body, life and growth in nature in cycles.For example theory of traditional Chinese medical science, in discussing chronic obstructive pulmonary disease pathology, main judgement is with gas
Based on void, it is believed that Lung Qi deficiency is the internal factor occurred.Phlegm, the stasis of blood are pathological products and pathogenic factor important in the course of disease.Think
The lung-distension because inside having pent-up, first hindering lung qi, outer multiple sense is evil, and lung qi must not give vent to, then the lung-distension is made.Lung qi virtual loss, it is powerless to push
The defeated cloth of operation of body fluid, body fluid stop gathering, then it is wet to give birth to phlegm unboiled water life.Spleen-Qi Deficiency, transportation capabilities imbalance, body fluid must not defeated cloth, gather and
At phlegm.Phlegm coming from spleen, lung being reservoir of phlegm.In addition decline of kidney-YANG, disablement gas row water, and polywater is at phlegm;Phlegm sheet, water
, it is derived from kidney, the work(of phlegm is wet, main in spleen;Phlegm trip, gas store in lung.Phlegm wet stops up resistance, and Qi dysfunction causes the stagnation of the circulation of vital energy, gas
It is inverse;Again because of the mutual root alternate of qi and blood, then blood stasis, the turbid retardance of phlegm hinder blood to run, also cause blood stasis the stagnation of the circulation of vital energy.
In doctor trained in Western medicine theory, it is believed that oxygen reserve is few in human body, it is necessary to dependent on the supply of external environment oxygen and by exhaling
The intake and transport of oxygen are constantly completed in suction, blood circulation, to ensure the needs of cell.When tissue cannot get abundance
Oxygen, or when cannot make full use of oxygen, cell, tissue, the metabolism of organ, function, even morphosis may all be abnormal change
Change, this pathologic process is known as anoxic.Such as cerebral anoxia.Under anaerobic conditions, the pathological change occurred at first is brain
Make the forfeiture of current potential, extremely sensitive to anoxic, tolerance is worst.The current potential of nerve cell is only just opened for more than ten seconds after anoxic
Begin to change.The mode that cytopathic effect inhibition assay shows under anaerobic condition is all that entanglement occurs for ion transport mechanism.Cellular energy source
When glycometabolism, second is that the energy after energy-rich phosphate organic compound glycolysis.Sugar directly decomposes oxidation and generates free energy, human body
A most important link is exactly atriphos (ATP) during interior anaerobic metabolism.ATP is an energy storages library, can be with
It is energized directly to cell without slaking, oxidation.But the reserves of ATP are few in brain tissue, if under complete anaerobic condition,
ATP just runs out of in a few minutes in brain tissue.There is no an ATP energy, sodium ion cannot be from being transferred to outside film into the cell, Bu Nengwei
Normal film potential is held, cranial nerve cell just loses function.Sodium is about 40-44mmol/kg in normal human, extracellular
The 44% of total sodium amount is accounted in liquid, and 9% is accounted in intracellular fluid, 47% is accounted in marrow.Internal sodium has exchangeable sodium and non-exchange sodium,
Exchangeability accounts for 75%, and non-exchange sodium accounts for 25%, and the latter's calmness is in bone.Sodium ion holds extracellular fluid in extracellular fluid
The maintenance of amount and osmotic pressure plays an important role, also critically important to the activity of muscle.Maintain intraor extracellular sodium concentration difference, mainly according to
The effect of Na+-K+-ATP enzymes (i.e. Na+-K+ pumps) on cell membrane.Since the Na ion concentration outside cell membrane is than in film
It is about three times larger, and potassium ion is higher than in film outside film, in the active procedure of nerve cell, potassium ion and sodium ion have temporarily
A large amount of outflows.Potassium ion is since the concentration inside and outside film has favorable balance, so depending merely on variation and the osmotic pressure of permeability of cell membrane
Difference, so that it may to be flowed into outside film out of film.And the case where sodium ion, is exactly the opposite, Na ion concentration is higher than outside film in film, sodium
The outflow of ion is inversely to carry out, and depends merely on dispersion and mesh is not achieved.It must rely on a kind of mechanism of similar water pump that could carry out,
As the water in well must can just be drunk up with water pump, energy, i.e. cellular energy ATP are needed.
Sodium balance disorder is often accompanied by the Balance disorders of water in body.The eubolism and balance of water and sodium are maintained in human body
An important factor for ambient stable.If intracellular sodium ion is more and more, chlorion just enters in film, because chlorion is can be with
Cell membrane is freely penetrated, positively charged sodium ion and electronegative chlorion meet and become sodium chloride, intracellular osmotic pressure
It is continuously improved.Body can only allow moisture content to enter intracellular, moisture makes cell again to keep permeable pressure head inside and outside cell membrane to balance
Volume increase, then cell starts oedema, and here it is generate brain edema after anoxic.Though human brain weight is only
The 2% of weight, but its oxygen demand is a quarter of Whole body oxygen consumption to 1/5th.If it is acute anoxia, can also
The increase for causing cerebral blood flow (CBF) causes vascular wall and brain Barrier Permeability to increase, this can also make brain cell interstitial edema, add
The increase of sodium, water in brain cell, causes Brain circlulation by obstacle and causes brain edema, and here it is the originals for leading to altitude coma symptom
Cause.In general, the main reason for edema it is anoxic, infection or acid poisoning.Its mechanism is:When anoxic mitochondria by
Damage makes ATP generate and reduces, and then obstacle occurs for the sodium in cell membrane, potassium pump function, causes Na+ and water in endochylema to increase, together
Shi Fasheng pathological changes.It is in vesica shape in swelling such as electric mitochondria intracytoplasmic under the microscope, endoplasmic reticulum;The observable under light microscopic
It swells to diffusivity cell, endochylema is light to be contaminated, is limpid, and karyon is normal but sometimes slightly larger, and medically the cell of severe edema is referred to as
Balloon sample becomes.The sodium in anoxic initial stage brain cell membrane, potassium pump function occur obstacle, and maintain the smooth of brain vessel blood in order to prevent
It is logical, the outflow for promoting intracellular sodium ion is just must try to, the combination of chlorion and sodium ion is prevented, prevents the entrance of water.This
It is Deterioration mechanism of the brain organ after anoxic, certainly, also that's about the size of it for the anoxic mechanism of other organs.
Lung organ for another example.Lung position highest in viscera, Chinese medicine claim lung covering other viscera, easily invade sense by exopathogen.The lobe of the lung
It is delicate and can not resist cold heat, therefore it is referred to as saying for " tender dirty " to have lung.Think that lung is the position of storing soul, the master of QI;It is so-called ' in the green ', mainly
The operation of lungs should be referred to freely.Because lung seeks hundred arteries and veins, the blood of whole body is all flowed through by hundred arteries and veins in lung, transpulmonary breathing, is carried out
The exchange of the pure and impure gas in inside and outside, one exhales a suction, the pure and impure transporting of department.Some researches show that, Pulmonary Vascular to the reaction of anoxic with
Body blood vessel is opposite.Alveolar hypoxia causes lung parteriole to shrink, and the alveolar blood flow of anoxic is made to reduce.Anoxic causes Pulmonary Vascular to shrink
Mechanism it is more complex, theoretical point view is different, than if any sympathetic nerve effect say, it is believed that sympathetic activation caused by anoxic can be made
Cause vascular contractile response for pulmonary vascular α receptors;There is humoral factor effect to say, it is believed that anoxic can promote loose in lung tissue
Cell, pulmonary alveolar macrophage, vascular endothelial cell etc. discharge the vaso-active substances such as histamine, Prostaglandins and Leukotrienes, wherein
What is had can shrink Pulmonary Vascular, some expansion blood vessels etc..There is theory to think that anoxic directly acts on vascular smooth muscle, because anoxic makes
Smooth muscle cell membrane increases the permeability of Na+, Ca2+, promotes to flow in Na+, Ca2+, leads to myocyte's excitability and shrinkage
Increase, it is possible to there is more blood plasma to filter out capillary and enter in lung tissue gap and alveolar, liquid in alveolar is made to gather,
To form pulmonary edema.Hypoxic pulmonary vasoconstriction is the result of multifactor functioning in a word.
Under the related theoretical direction of traditional doctor trained in Western medicine, after to anti anoxia on the AD-targeted drugs of pulmonary hypertension, doctor trained in Western medicine
It focuses mainly on reducing pulmonary hypertension.But while reducing pulmonary hypertension, (diastole) body circulation pressure is also reduced,
To affect right ventricle perfusion and body circulation oxygen supply, certain important organ blood vessel dilatations are aggravated, have made the blood stasis of blood stagnant instead.
When the severe depletion of oxygen of plateau, oedema can occur for interstitial lung, alveolar wall, cause oxygen that obstacle occurs to the disperse of cell tissue, serious to lack
Oxygen can cause plateau pneumochysis.Anoxic is very big on the easypro contracting activity of local pulmonary circulation blood vessel influence, and acute or chronic anoxic can
So that pulmonary circulation vessel retraction, resistance of blood flow is increased, pulmonary arteriole is caused to shrink extensively, pulmonary artery (partial circulating) pressure significantly increases,
Pulmonary capillaries pressure also increases.And anoxia condition lower body systemic vascular diastolic pressure is just with pulmonary circulation pressure on the contrary, lung follows
Ring pressure is high, and body circulation (systemic circulation) presses diastole.I.e.:Pulmonary Vascular (partial circulating) and body blood vessel are Pulmonary Vasculars to the direct reaction of anoxic
It shrinks and body vasodilation.The diastole of anoxic aorta posterior, cerebral vasodilators, the former causes pulmonary hypertension, pulmonary heart disease, the latter to make
Returned blood volume increases and promotes pulmonary encephalopathy occurrence and development.Western medicine uses vasodilator, will aggravate body vasodilation and brain blood
Pipe further expansion.
Invention content
The purpose of the present invention is to provide a kind of definite ingredients, nontoxic to overcome the shortcomings of existing resist oxygen lack product technology
The nutrient combination that can improve body fatigue resistance, resist oxygen lack.
The further domestic and international document in relation to anti-fatigue anoxia-tolerance of analysis, we, which are concerned about hypoxic conditions, can pass through difference
Approach generate a large amount of free radical in vivo, since the property of free radical is very active, make the lipid mistake in internal cell membrane
Oxidation, cell are in mixed acid toxic state, and body mitochondrial is damaged, and so that atriphos (ATP) is generated and reduce, cause
Sodium balance is disorderly, and with the Balance disorders of body fluid (water), and carbon dioxide buildup, disperse are in intracellular and combined with cell body fluid
Hydrogen ion and bicarbonate ion are generated, causes body tissue acidity to increase, body tissue is made to lose the balance of soda acid quickly,
Cell pH value declines, oedema, and sodium, potassium pump function in cell membrane occur obstacle, causes Na+ and water in endochylema to increase, Jin Erfa
A series of raw Hypoxic pathological changes.Anoxic makes smooth muscle cell membrane increase the permeability of Na+, Ca2+, promotes Na+, Ca2+
Interior stream causes myocyte's excitability to increase with shrinkage, and the degree bigger of the incomplete aerobic metabolism of body causes body tissue each
Carbon dioxide cannot wash away away in time in organ, form the delay of carbon dioxide, and internal carbon dioxide buildup and anoxic are simultaneously deposited,
This two groups of pessimum states and deposit, so that each organ of body especially respiratory apparatus, brain organ obstacle is occurred, pulmonary ventilation rate reduces,
Cerebral blood flow (CBF) reduction, capilary Partial occlusion, pulmonary artery forms high pressure, or even brain edema, high altitude pulmonary edema, Combination occurs
The appearance of the serious pessimum symptom such as acid poisoning.
The a large amount of free radicals generated in order to prevent by anoxic prevent the lipid peroxidation in internal cell membrane and mixed acid
Poisoning symptom, it is necessary to intervene the health operating of the sodium, potassium pump function in anoxic incipient cell film in advance, and maintain each organ blood vessel
Blood flow it is unimpeded, be the normal outflow for trying to promote intracellular sodium ion at hypoxic conditions initial stage, this be prevent hypoxic conditions after
Supervention is opened up and the effective way of extension.We are while with reference to doctor trained in Western medicine theory, further according to theory of traditional Chinese medical science, with yin, yang, table,
In, cold, heat, empty, the real eight principal syndromes usher into the dialectical Analyses of row defensive-qi-nutrient-blood.
Seldom it is simple and isolated though hypoxic conditions have respectively different exterior syndromes, but complicated close that be mutually related
Therefore system should link up during dialectical and be analyzed, take into account the different mechanisms of traditional Chinese and western medicine theory, correctly judge,
Comprehensive prescription means are taken, to carry out appropriate treatment
This prescription provide it is a kind of formula rationally, definite ingredients, nontoxic anti anoxia, fatigue proof health products, by activity
Ingredient D-ribose, L-arginine, taurine, American Ginseng medicinal extract, mono- carnitines of L, L-Ascorbic Acid L-O-Phosphate, polyfructosan and rectify
Taste agent etc. is into the health-care food being grouped as.The formula is new by looking into, and not yet at home and abroad pertinent literature retrieves the present invention
Prescription document.
This prescription selects active constituent D-ribose, L-arginine, taurine, American Ginseng medicinal extract, mono- carnitines of L, vitamin C phosphorus
Acid esters magnesium, polyfructosan select rational prescription efficient combination ratio, so that prescription effect as functional component by testing sieve
Synergistic effect is generated, to effectively play the fatigue proof health-care effect of anti anoxia, inferior health person is helped or enters plateau person weight
The new enough energy obtained needed for vital movement, restores the due vigor of body.
The corrigent is selected from the acceptable auxiliary material of food, and in particular national regulation can be used for the additive of food, preferably
Following substance:Mannitol, sodium citrate, potassium citrate, Grape Skin be red, sodium benzoate, aspartame, honey element, xylitol, sweet tea
Chrysanthemum glycosides, strawberry essence, erythrose alcohol, flavoring pineapple essence, orange flavor, peach flavor, green apple essence, watermelon essence, dioxy
Change carbon etc., wherein optimization citric acid potassium, sodium citrate, aspartame, stevioside, strawberry essence, sodium benzoate.The above is rectified
Taste agent substance, can be single substance, can also be two kinds or two or more mixtures.
According to this group of formula, each component is analyzed in conjunction with document, it is as a result as follows:
D-ribose:A kind of pentose is present in all cells, is the important of metabolism and energetic supersession in organism
Substance.D-ribose is the constituent of the nucleoside derivates including the various RNA such as mRNA, RNA, 5sRNA and many coenzyme.Nine
The ten's Mos, it has been found that D-ribose has the ability of fast quick-recovery musculature ATP synthesis.ATP is the general energy in human body
Amount, when carrying out physical exertion and anoxic, ATP can be degraded to precursor substance, these precursor substances can be lost in from cell,
So that ATP is unable to reach normal level in a short time, makes one to feel powerless, fatigue.It is any to cause muscle cell oxygen pressure local
What anoxic reduced will loss cellular energy deposit.The reduction of energy can destroy the flow direction management of calcium, cause muscular tone, deadlock
Firmly, pain and fatigue.The increase of intracellular Ca++ causes the loss of K+, this will stimulate on cell membrane feeling of pain by position device.
Pain further increases muscular tone, aggravates energy loss, leads to vicious circle.Chronic ischemia, anoxic or frequent
High pressure training can be such that purine is lost in from cell, and reduce cellular energy load.The frequency and severity of histanoxia
Determine the speed and degree of energy loss.For unbred people, a high pressure training is just enough to exhaust energy storage
It is standby, cause muscle rigidity and pain.For trained, more days frequent high intensity exertions also will produce it is this after
Fruit.For sportsman, depleted of energy can cause to overtrain, and cause the physiological damage of myalgia, weakness and muscle.D- cores
The intake of sugar can prevent the loss of ATP precursor substances, the rapid level for restoring body ATP, and body is enable to obtain life rapidly
The required enough energy of life activity.High intensity after training, the level of ATP can reduce by 60% one 70% in musculature,
Being restored to normal level needs 3 day time, if having eaten D-ribose, can in 24 hours the normal ATP levels of fast quick-recovery.D-
Ribose can also make the fast quick-recovery ATP of the cardiac muscle for being subjected to ischemic injuries horizontal.When tissue surface is to Metabolic stress, ribose is supplemented
Cell energy can be accelerated to restore, stimulation purine metabolism, hypoxic condition can cause muscle function and the various physiology shapes of performance
Condition, including:
1, muscle rigidity, pain, weakness and restore slow from exercise;
2, cell membrane and muscle fiber damage;
3, oedema, swelling and electrochemistry are chaotic;
4, protease and phosphatidase attack cells;
5, the institutional frameworks such as free radical and damage cell membrane, mitochondria are formed;
6, Delayed Onset Muscle Soreness (DOMS);
7, tired;
8, the synthesis such as hereditary macromolecular is postponed.
By keeping cell oxygen energy load, the loss of cell purine is controlled, increase oxygen energy is synthesized and remedied, ribose energy
Enough mitigate these symptoms, accelerate to restore, and compensate due to overtrain or altitude environment caused by cell and tissue damage.
L-arginine:Known according to document, it is exogenous to give nitric oxide precursors L-arginine, hypoxic pulmonary can be alleviated
Vascular adhesion molecule-1.Clinically start to treat lasting fetal circulation and meconium aspiration syndrome etc. using the method that NO is sucked
Disease, and obtained preliminary efficacy.But NO suckings are costly, and instrumentation is complicated, therefore limits its clinical application.
L-arginine is the precursor of NO synthesis, it is catalyzed through NO synthase after entering in vivo and generates NO.In recent years about using L-
The research that arginine intervenes hypoxic pulmonary vascular structural remodeling is more and more paid attention to, and many results of study show L- essences
Propylhomoserin makes pulmonary arteries of hypoxic pulmonary hypertensive rats pressure be substantially reduced, and lung thin vessels flesh degree is substantially reduced, and lung is middle or small
Flesh type artery RMT and RMA are substantially reduced, and pulmonary artery collagen expression is reduced, and the change of pulmonary artery ultra microstructure is relieved.
Experiment in vitro confirms that NO has direct repression to the proliferation of vascular smooth muscle cells, prompts L-arginine intervention
One of the mechanism of hypoxic pulmonary vascular structural remodeling may be by the direct effect of NO;On the other hand, experiment in vitro is shown, NO
The synthesis and secretion of huve cell ET-1 are can inhibit, and it is horizontal to reduce blood plasma ET-1.NO is to Chronic Hypoxic Rats lung
Artery ET-1 gene expressions have inhibiting effect.And ET-1 is presently found strongest contracting vasoactive polypeptides in vivo, and have
There is strong rush vascular smooth muscle cell proliferation.Thus prompt indirectly, L-arginine intervene hypoxic pulmonary vascular structural remodeling
Another mechanism be by promote NO synthesis, to promote vascular smooth muscle cell proliferation factor ET-1 inhibition make
With.
Taurine:Taurine is the cell-protecting of wide spectrum, has protective effect to cellular damage caused by anoxic.Taurine
Anoxic body ET-1 and ACE secretion is can inhibit, increases NO and SOD levels, reduces pulmonary artery pressure, mitigate cardiopulmonary tissue damage.
Taurine can weaken inhibited proliferation of the anoxic to pulmonary artery endothelial cell, and the rush arteria pulmonalis smooth muscle cells of anoxic is inhibited to increase
The effect of growing is allowed to close to normal oxygen level.
Taurine is a kind of sulfur-containing amino acid in animal body, but is not protein constituent, also known as taurine, ox courage
Element.The study found that taurine is the active material for adjusting body normal physiological activity, has the function of to maintain normal vision, maintain
Body osmotic balance adjusts cell calcium balance, related with the mobility of cell membrane.Taurine is hypoglycemic, adjust nerve conduction,
Endocrine Activity is participated in, lipid digestion is adjusted and absorbs, increase contractile ability, improve body immunity, enhancing cell
The extensive biological actions such as film oxidation resistance, protection cardiac muscle cell.Taurine has the dynamic regulation and control of detoxication, calcium current, bile
A variety of effects such as sour combination, osmotic pressure regulation and control, stabilizing cell membrane.There are anti-arrhythmia, myocardial preservation in cardiovascular system
With the equal functions that reduce blood pressure.Relatively broad to action of the heart, exogenous supplement taurine can fight a variety of of heart
Pathological state.Mechanisms of Taurine on Cardiaovascular System has a series of unique functions, mainly protects hypoxic-ischemic cardiac muscle, reinforces left ventricle
Function increases myocardial contractive power, safeguards the stability of mitochondrial membrane of myocardium, anti-arrhythmia, prevents congestive heart failure, drop
Low blood pressure, reduction cholesterolemia, raising high-density lipoprotein, atherosclerosis etc..And cell protective effect is then ox
Sulfonic acid resist myocardial ischemia, the exposure basis of anti-arrhythmia, reperfusion injury, myocardial preservation etc..Taurine other
Function also has lipid peroxidation product when can reduce movement, promotes the increase of body antioxidase activity after movement.It participates in
Pulmonary Vascular caused by anoxic is reconstructed, and has certain preventive and therapeutic effect to hypoxic pulmonary hypertension.Taurine is that the cell of wide spectrum is protected
Protect medicine, thus it is speculated that also have protective effect to cellular damage caused by anoxic.
Taurine can improve NO yield by protecting cells from anoxia-induced apoptosis.Research is it is also shown that taurine can make anoxic
Caused L-arginine turn-over capacity obstacle is restored, and Transport Rate, nitric oxide synthetase (NOS) activity of L-arginine are made
Increase, NO generations increase.NO also has other than adjusting antiotasis and inhibits blood platelet and haemocyte adherency, anti-lipid peroxy
Change and protect the function of cell.
American Ginseng:American Ginseng is the dry root of araliaceae ginseng plant's American Ginseng, cool in nature, sweet in flavor, slight bitter, the thoughts of returning home, lung,
Kidney channel has the effect of boosting qi and nourishing yin, clearing heat and promoting fluid.It is antifatigue, anti-that modern pharmacology research finds that American ginseng extract has
Oxidation, resisting stress inhibit platelet aggregation, adjust the effects that blood glucose.Saponin component in American Ginseng can effectively enhance maincenter
Nerve excitability, reach it is with all worries set aside with fixed attention, dispelling fatigue, enhancing memory the effect of, the rehabilitation to chronic fatigue syndrome
With positive therapeutic potential.There are some researches prove American ginseng total saponins have function of resisting myocardial ischemia, and there are a variety of pharmacology to live
Property, central nervous system function and heart body are such as adjusted, anti-arrhythmia cordis, resists myocardial ischemia, anti anoxia, antifatigue, anti-answer
Swash, enhance the effects that immune function.It eliminates oxygen radical, and anti-lipid peroxidation reaction may be the two oxygen lack resistant function
Main pharmacological mechanism.American Ginseng Central nervous has certain excitement and antifatigue effect, improves cell oxygen carrying capacity, enhancing breast
The vigor of acidohydrogenase is conducive to the further oxygenolysis of lactic acid in blood, enhances immune system ability, and enhancing human body is externally got along well
The resistance and adaptability of hypofunction caused by internal factor, that is, enhance stress ability, to improve resisting oxygen lack,
The phagocytic function of macrophage is improved, the formation of body specific antibody is promoted, improves the division of T lymphocyte, bone-marrow-derived lymphocyte,
The cytotoxicity for significantly increasing TIL cells stimulates the secretion of interleukin 2, enhancing natural killer cells (NKC)
Activity improves the level of cyclic adenosine monophosphate.
L-carnitine:It is a kind of amino acid being widely present in human body, is the component part of food, it is considered to be human body generation
The nutrient of required " biostearin " thanked.
1, " conversion " effect of l-carnitine
The main Physiological Function of l-carnitine is exactly that the FFA (free fatty) of transhipment activation enters mitochondrial matrix, and fat
Main energy sources substance when fat is low-intensity prolonged exercise again, fat releases FFA by " mobilization " in adipocyte.FFA's
Oxygenolysis mainly has 3 big steps:(1) it activates;(2) beta oxidation;(3) tricarboxylic acid cycle, rear 2 step carry out in mitochondria.
FFA, which is entered by Skeletal Muscle Cell when mitochondrial oxidation decomposes, needs the help of carrier-carnitine on mitochondrial membrane that could enter, because
It is not penetrating to FFA for mitochondrial inner membrane.The utilization of FFA can be enhanced by increasing the carnitine levels in muscle, in addition, the increasing of carnitine
Adding can promote pyruvate oxidation to become acetyl-COA rather than receive NADH+H+ and be reduced into lactic acid, be generated to reduce lactic acid,
And then improve sports achievement.
2, acyl group COA/COA ratios in mitochondria are adjusted, the oxidation of pyruvic acid is promoted
The short chain or Medium chain fatty acyl group COA that oxidation or other mitochondrial metabolism processes generate, pass through acyl group transfer reaction
Fatty acyl carnitine is generated, fatty acyl carnitine transports mitochondria under the action of enzyme, is risen into the circulatory system and adjusts chondriosome acyl COA/
The effect of COA ratios.The stabilization of acyl group COA/COA ratios, plays an important role to energetic supersession in mitochondria.If mitochondrial matrix
In acetyl group transport not in time, acetyl-COA/COA ratios rises, and has inhibiting effect to pyruvic dehydrogenase.Carnitine can improve
The activity of pyruvic dehydrogenase promotes the oxidation of glucose to utilize, and the acyl group COA that can also improve branch is combined into carnitine
Ester is conducive to its oxidation and utilizes to reduce inhibition of the excessive branched chain acyl COA to branch pyruvic dehydrogenase.
3, l-carnitine and Mitochondrial H+- ATP enzyme (F0F1ATP enzymes)
ATP levels are to determine the principal element of locomitivity in cell mitochondrial.As the enzymatic lysis of macromolecular, core be aggregated with
And the formation of vesica, it is required for the participation of a large amount of ATP enzymes, the source of ATP mainly makes line grain by aerobic exercise in mitochondria
Body oxidative phosphorylation, supplement carnitine add rational aerobic training that body mitochondria quantity is caused to increase, and the activity of ATP enzyme improves,
The generation of ATP increases, and SOD activity significantly increases, and MDA contents decline, and lipid peroxide habituation, aerobic capacity obtains
Improve, therefore cellular energy supply increases, and improves anti-fatigue ability.L-carnitine can increase skeletal muscle mitochondrial metabolic enzyme activity,
Accelerate the clearance rate of free radical, the generation of delayed motion fatigue.Research has shown that supplement l-carnitine can make mouse power exhaust swimming
The expression quantity of tricarboxylic acid cycle rate-limiting enzyme increases in skeletal muscle after movement, and oxidation resistance enhancing improves locomitivity.Widely
Human body and zoopery show that l-cn can also reduce blood fat, promote myocardial metabolism and improve heart function, nerve conduction, surrounding
The ischemia symptom of arterial disease, and the effects that improvement physical efficiency.
L-Ascorbic Acid L-O-Phosphate:L-Ascorbic Acid L-O-Phosphate advantageously forms and maintains collagen, keeps body all thin
Born of the same parents combine, and vitamin C is the main matter of collagen, the important composition of cytoprotection layer connective tissue, but simultaneously calcium,
Magnesium ion is also indispensable, as having condensation effect to pectin, calcium ions and magnesium ions vitamin C connective tissue can be made strong and
It is flexible.Connective tissue is destroyed when hypovitaminosis C, is lacked calcium ions and magnesium ions and is allowed to become fragile.Cell just lacks at this time
Defence capability.Ascorbic detoxication is and to invade the combination of human organism's Toxic, is gone out with homaluria.When people catches,
Vitamin C content can be reduced and be disappeared in blood, and body disease-resistant can be helped by taking enough vitamin Cs.The vitamin C of large dosage
The brittleness of Blood Cholesterol and capillary can be reduced.
Vitamin C can effectively block chain reaction caused by free radical, to play the role of remove free radical, have pair
Play a part of antioxidant in body.
Magnesium ion in L-Ascorbic Acid L-O-Phosphate, as enzyme confactor participate in vivo all energetic supersessions, activation and
The about a variety of enzyme systems of catalysis.Meanwhile magnesium ion has activated the adenyl cyclase on cell membrane, and pass through activated protein kinase
And enzyme, stablize film potential, to release airway spasm, improves anaerobic condition, improve pulmonary circulation.Have been demonstrated that magnesium is almost participated in
Each step of protein synthesis participates in the synthesis of immunoglobulin and participates in activating complement, adjusts the phagocytosis work(of phagocyte
It can and adjust the maturation and function of lymphocyte.Therefore, magnesium ion also participates in adjusting body's immunity, increases disease resistance.
Activator of the magnesium as enzyme, enzyme are a kind of very important chemical substances in organism, are that one kind is generated by cell
, specific proteins with catalytic activity and high specificity, it participates in and controls all metabolic processes in life, and
Some enzymes can just be activated in the presence of must have metal ion, its catalysis of competence exertion, Mg2+ ions are exactly this fermentoid
A kind of activator.
Magnesium and calcium have formed special partnership during producing atriphos (ATP).It is known that ATP
It is a kind of bio-energy of preciousness in human body, is the power producer that people are engaged in activities, this online grain of important molecule
It generates in vivo, is a kind of allantoid, very small " energy plant ", is deposited in inside living cells, if without it, it is living thin
Born of the same parents just cannot get " can flow " of the required abundance of proper motion.Magnesium is cardiovascular umbrella, and expansible blood vessel prevents artery
Sudden contraction makes blood pressure keep stablizing.Energy atherosclerosis, participates in the contraction process of cardiac muscle, when content of magnesium in cardiac muscle
When reduction, myocardial necrosis can be caused.For a long time, magnesia mixture clinically be used to rescue various types of arrhythmia cordis, severe
The patient of hypertension, hypertensive encephalopathy and acute myocardial infarction complicated heart failure.Magnesium has sedation to brain centres nerve,
Nervous psychology can be eliminated, is eased off the pressure, impatience is released, helps and fall asleep.Magnesium has also undertaken the function of loosening all muscles, is called natural
Tranquillizer can include the facial muscles often in tense situation with loose muscle.
Since above-mentioned several drugs are existing natural molecules in body, the equal nonhazardous of human body is acted on, can become anti-and lack
The health products of the fatigue proof long-time service of oxygen.
Experiment 1, influence of the tested material to mouse entirety oxygen demand
1, material:
Reagent:
Tested material:Oxygen-deficient endurance fructose powder, trial target, 6 grams every bottle.
Positive control drug:Compound danshen dripping pills, lot number:160320, specification:The weight 27mg per ball, Tian Shili pharmacy group stock
Part Co., Ltd.
Soda lime, Shanghai the May 4th chemical reagent Co., Ltd, specification:500g, product batch number:160807.
Experimental animal:ICR mouse, male, 22-24g, SCXK (capital) 2014-0013 are ground purchased from Chinese food drug assay
Study carefully institute.
2, method:
Animal adaptability feed 1 week after be randomly divided into blank control group, compound danshen dripping pills control group (200mg/kg),
Stoste control group (tested material B), tested material (A is dissolved in B) (0.5g/kg, 1g/kg, 2g/kg), every group 15, successive administration
15 days.
After last dose 1 hour, animal is put into the closed wide-mouth bottles of 250ml for being pre-loaded with 30g soda limes, uses silica gel
The rubber stopper for being connected with buret is sealed with wide-mouth bottle, the buret other end is inserted into water.It records in 0-5min burets respectively
Liquid level lifting height in buret when liquid level lifting height, death time of animal, death calculates the total oxygen consumption of survival period after experiment
Amount/20g, 0-5min oxygen demand/20g.
3, data processing:
Data are indicated with mean+SD, and T-test inspections are carried out between group.
4, result:
When normobaric hypoxia, due to aoxidizing incomplete acidic metabolite, CO2Accumulation, can stimulate chemocepter or in
Pivot nerve, causes exaggerated respiration to be accelerated to reflectivity, and heartbeat is reinforced, and cardiac output increases, and blood is redistributed to ensure internal organs
Blood supply.In this experiment under the conditions of normobaric hypoxia, by calculate special time period mouse oxygen demand, the death time and
Survival period oxygen demand illustrates the resisting oxygen lack of tested material.
The experimental results showed that compared with Normal group, stoste control animals death time of tested material extended,
Oxygen demand/20g and the total oxygen demand/20g of survival period increased in 0-5min, but statistics unknown significance difference (P >
0.05), positive drug Danshen Root dropping ball and tested material 2g/kg groups, death time of animal are obviously prolonged, and the total oxygen demand/20g of survival period is bright
It is aobvious to increase, the significant difference of statistics (P < 0.05) (being shown in Table 1)
The influence (n=15) of table 1, tested material to mouse entirety oxygen demand
Compared with model group, * * P < 0.01, * P < 0.05
5, conclusion:
Tested material is under 2g/kg dosage, and successive administration is after 15 days, the difference in the determination experiment of mouse entirety oxygen demand
Index has different degrees of resisting oxygen lack.
Experiment 2, influence of the tested material to mouse swimming time
1, material:
Reagent:
Tested material:A, white powder;B, black liquor.
Positive control drug:Compound danshen dripping pills, lot number:160320, specification:The weight 27mg per ball, Tian Shili pharmacy group stock
Part Co., Ltd.
Soda lime, Shanghai the May 4th chemical reagent Co., Ltd, specification:500g, product batch number:160807.
Experimental animal:ICR mouse, male, 22-24g, SCXK (capital) 2014-0013 are ground purchased from Chinese food drug assay
Study carefully institute.
2, method:
Animal adaptability feed 1 week after be randomly divided into blank control group, compound danshen dripping pills control group (200mg/kg),
Stoste control group (tested material B), tested material (A is dissolved in B) (0.5g/kg, 1g/kg, 2g/kg), every group 10, successive administration
15 days.
After last dose 1 hour, by the iron wire for 9% weight of bearing a heavy burden with animal, it is put into depth of water 20cm, 30 DEG C of water temperature
Swimming in bucket, observation mouse, which is swum to power, to exhaust and (cannot float within 10 seconds under water), when which is the swimming with a load attached to the body of mouse
Between.
3, data processing:
Data are indicated with mean+SD, and T-test inspections are carried out between group.
4, result:
The generation of exercise induced fatigue is to cause the reduction of muscular contraction force caused by a series of biochemical changes of body by movement,
The most direct performance of the generation of sports fatigue is the decline of body movement endurance.The time of swimming with a load attached to the body, which can be used as, in this experiment sentences
The objective indicator of disconnected mouse muscle power strength, anti-fatigue ability.
Compared with Normal group, Danshen Root dropping ball (200mg/kg) group, tested material (1g/kg, 2g/kg) group compare model
Group walking weight load is obviously prolonged, and statistics has pole significant difference (P < 0.01).(being shown in Table 2)
The influence (n=10) of table 2, tested material to the mice burden swimming time
Compared with model group, * * P < 0.01, * P < 0.05
5, conclusion:
Under 1g/kg and 2g/kg dosage, successive administration has the mice burden swimming time and obviously prolongs tested material after 15 days
Long effect, has certain antifatigue effect.
Experiment 3:Anxious toxicity test and the report of assessment Experimental Pathology
1, test sample and reference substance
1.1 test sample information
Title, abbreviated name, code name:Substituted phenyl-lactic acid fructose powder (oral solution)
Lot number:160708
Content or purity:60%~95%.
Physicochemical property and biological nature:Substituted phenyl-lactic acid fructose powder is white powder.
Preservation condition:(10-30 DEG C) preservation of room temperature
The term of validity:18 months
1.2 reference substances/experiment solvent, emulsifier and other medium informations
Test sample title, abbreviation, code name:Sodium carboxymethylcellulose, CMC-Na
Content or purity:Chemical pure (CP)
Physicochemical property and biological nature:White powder
Preservation condition:(10-30 DEG C) preservation of room temperature
Manufacturer:Sinopharm Chemical Reagent Co., Ltd.
The preparation of 1.3 test samples and reference substance
When preparing test sample or reference substance, wearing vest, wears masks at gloves.
The preparation of test sample:It uses 0.5% sodium carboxymethylcellulose as solvent, Substituted phenyl-lactic acid fructose powder is configured to dense
Degree is the suspension of 0.125g/ml.Useful blender is stirred in process for preparation.
The preparation of reference substance:Appropriate sodium carboxymethylcellulose is weighed, distilled water is gradually added into, stirs evenly and is configured to
0.5% carboxymethylcellulose sodium solution.
The analysis of 1.4 test samples and reference substance measures
It is analyzed without test sample.
The processing of 1.5 test samples to keep sample with remaining test sample
Test sample keeps sample, and all peace is commented after the test in addition to the sample that keeps sample, and remaining test sample is returned by consigner's requirement
Also.The remaining test sample preparation of experiment was returned to test articles handling department on the experiment same day and was uniformly processed.
The test sample amount that 1.6 this experiment use altogether is 10.0g.
2 experimental systems
2.1 animals use management and protection
Conservator is assessed and approved by U.S.'s International Laboratory Animal in national Beijing drug safety evaluation research center
Meeting (Association for Assessment and Accreditation of Laboratory Animal Care
International, AAALAC) International Certification, all animals in this research center are according to International Laboratory animal welfare behavior
Criterion《Guide for the Care and Use of Laboratory Animals》It is required that carry out experimental animal use with
Management.
2.2 experimental systems and selection reason
What People's Republic of China's national health and Family Planning Committee formulated《National food safety standard food security
Property toxicological evaluation program》(GB15193.1-2014) rat is recommended.SD rats are the recognized standards in toxicologic study
One of animal, this experiment use SD rats.Consigner also agrees to carry out acute toxicity test using this kind of animal.
2.3 experimental animal
Kind:Rat
System:SD
Animal level:SPF
Gender and quantity:Actual use female 20 (orders 23), and actual use male 20 (orders 23).
Animal age:7-8 weeks
The weight of animals range:Female Body Weight is ranging from the end of quarantine:146.1g~164.6g, it is male at the end of quarantine
Property weight range is:143.2g~169.2g.
Animal origin:Beijing Vital River Experimental Animals Technology Co., Ltd.
Animal productiong licensing number and issuing unit:SCXK (capital) 2016-0011;Science and Technology Commission of Beijing
Animal quality certification number (note, quality certification upper right corner serial number):No.11400700230613
Animal reaches and date received:2017-06-29
The raising of 2.4 experimental animals and management and its environmental condition
It raises in the Barrier Facility of national Beijing drug safety evaluation research center, Experimental Establishment quality certification approval number is
SYXK- (army) 2012-0019, room temperature control illuminate, 12 hours dark for 12 hours in 20-25 DEG C, humidity 40-70%.Raising
Mode is raised for rat box, and only per cage 2-5, cage for rearing poultry is the transparent mouse box of makrolon.Mouse box and pad twice are replaced weekly
Material.
2.5 feeds and drinking water
Feeding Beijing Australia of section pull together feed corporation,Ltd production standard expanded pellet diet.Freely ingest.It is supplied with drinking bottle
Enough reverse osmosis water (RO water), is freely drunk by animal.It is daily to replace cushion and drinking water.
2.6 quarantine procedures
All animals will be by the requirement of SOPA005 quarantine observation 3 days, within this time, the performances such as activity, diet of animal
No abnormality seen, animal is preceding through clinical veterinarian passed examination in use, and provides inspection report.
The recognition methods of 2.7 experimental animals
After animal reaches, animal is had received by the requirement of SOPA005.An independent quarantine flowing water is determined to every animal
Number.It is marked to animal by related SOPT019.When grouping a single experimental animal number is specified for every animal.Animal
And indicate animal number on cage card.It is identified using experimental animal number in firsthand information.
Quarantine before grouping:It is unified to use green cage card, and indicate experiment numbers and individual animals number;
After grouping:Group differentiation is carried out with different colours cage card, and indicates experiment numbers, test sample title, dosage, group
Not, gender, number of animals.
3 acute toxicity test of table is grouped animal identification
3, experimental design
The foundation of 1 experimental design
The data that 1.1 clients provide
The clinic trial scheme that client provides:
Quasi- dosage:People's recommended intake:0.05g/ kg body weights
Approach:It is oral
1.2 trial test results:Nothing
The file and document of 1.3 toxicity research guidelines
What State Food and Drug Administration worked out《Health food is examined and assessment technique specification》(May 1 in 2003
Day implement) and national health and Family Planning Committee formulation《National food safety standard food safety evaluation on toxicology
Program》(GB15193.1-2014).
2 experiment groupings
4 acute toxicity test packet design of table
Solvent control group:It gives solvent 0.5% carboxymethylcellulose sodium solution with test sample group same volume, is administered every time
Volume 20ml/kg is administered 3 times in 24 hours, amounts to 60ml/kg.
Given the test agent dosage group:Drug concentration:0.125g/ml, each administered volume 20ml/kg, 3 are administered in 24 hours
It is secondary, amount to 60ml/kg, dosage is 0.125g/ml × 60ml/kg=7.5g/kg, and people's recommended intake is:0.05g/kg, by body
Surface area calculates (method see reference document 4), is equivalent to 122 times of people's recommended intake.It is equivalent to people by kg body weight calculating
150 times (7.5g/kg/0.05g/kg) of quasi- dosage.
3 test samples and reference substance give
3.1 administration routes and method
Administered volume:Blank control group and given the test agent dosage group are 60ml/kg, 3 times a day, amount to 60ml/ daily
kg。
Administration frequency and time:It is administered 3 times in 24 hours, dosing interval 4~6 hours.
The time limit is administered:It is repeatedly given in one day (3 times a day)
Administration way:Before experiment on an empty stomach, animal empty stomach overnight (not water restriction).According to SOPT001《Large and small mouse is oral
Gastric infusion》Requirement operation.
The reasons why 3.2 administration routes and method choice
The selection reason of administration route:The clinical administration approach that client provides is oral, with the quasi- approach of people's clinic
It is identical.
The selection reason of administered volume:20ml/kg is the larger administered volume of rat toxicity experiment gastric infusion, and rat fills
Stomach maximum dosage-feeding is 20ml/kg, 20ml/kg/ times in this experiment, is given for 3 times, 60ml/kg/ days total.
The selection reason of administration frequency and time:《Health food is examined and assessment technique specification》Middle pertinent regulations.Daily
When being administered multiple, interval time is 4~6 hours.
The selection reason in time limit is administered:It presses《Health food is examined and assessment technique specification》In regulation, acute toxicity gives
The medicine time limit is 1 day.
4 observation indexs
4.1 general physical signs
On the day of gavage, close observation and the poisoning manifestations and feature, poison of each animal are recorded in a few hours especially after gavage
Property reaction occur and recovery time and death condition etc., later daily observation 1 time, be observed continuously 14 days.Observation index includes
Clinical symptoms (such as animal appearance, behavior, diet, the reaction to stimulation, secretion, excreta), death condition are (when dead
Between, it is dying before reaction etc.), changes of weight (1 day before gavage, the 2nd day after gavage, respectively weigh within the 5th day, the 8th day, the 15th day one
It is secondary, record the weight of animals variation, on the day of non-gavage animal dead or it is dying when should weigh) etc..All death conditions are recorded, are gone out
The initial time of existing symptom and symptom, severity, duration, changes of weight etc..
4.2 pathological study indexs and time
Gross anatomy carried out to all experimental animals, including within experimental period it is dead, be euthanized and try because dying
The animal put to death at the end of testing.When gross anatomy occurs abnormal, it should all record and carry out histopathological examination.
5 detection methods
5.1 body weight measurement
By SOPT006《The weighing standard practice instructions of rats and mice weight》, with Mettler-PB3001 electronic balances (Mei Te
Le-support benefit (Changzhou) Weight Equipment System Co., Ltd) measure weight.
5 statistical analyses
To weight, average value and standard deviation are calculated by group and gender.
4, brief summary:
General physical signs observation
Death condition:Without animal dead during experiment, all animals are living to deposit to when plan postmortem.
Clinical sign:After the 1st gavage, during the 2nd time and the 3rd gavage, given the test agent dosage group animal observes
There is a loose stools symptom, second day animal loose stools symptom disappears after gavage, and animal restores normal.Solvent control group animal clinical symptom is not
See exception.
Rat oral gavage Substituted phenyl-lactic acid fructose powder (oral solution) urgency toxicity test, solvent control group and given the test agent dosage group
Pathologic finding shows no obvious abnormalities change.
Referring to subordinate list 1 and subordinate list 3.
Weight:Average weight has no and the relevant effect of test sample processing.Differential magnitude between control group is slight, not
Reach significance,statistical level.
Referring to subordinate list 2 and subordinate list 4, attached drawing 1,2.
5, histopathologic examination
Animal system postmortem:Substantially postmortem when have no and the relevant exception of test sample.
Referring to attached report 1.
Under the conditions of determined by this experiment, tested material Substituted phenyl-lactic acid fructose powder (oral solution) is to the oral acute of rat
Toxicity dose is more than 7.5g/kg BW, LD50More than 7.5g/kg BW, 7.5g/kg BW are equivalent to the 150 of people's recommended intake
It (is calculated again by kg body weight).
6, statistical graph
1 clinical sign of subordinate list observes result statistical form
2 the weight of animals measurement result statistical form of subordinate list
Note:Data are in table
Description of the drawings
Attached drawing 1:Jenny changes of weight.Attached drawing 2:Buck changes of weight.
7, animal individual test data subordinate list
3 individual animals clinicing symptom observation result of subordinate list
4 individual animals body weight determination result of subordinate list
The advantage of the invention is that:
1, it is proven by putting into practice above, raw materials used is food additives or pharmaceutical grade raw material, and equal
For existing natural molecule in body, effect harmless to the human body can become the health products of the fatigue proof long-time service of anti anoxia.
2, prescription of the present invention selects rational prescription efficient combination ratio by testing sieve, so that prescription effect generates collaboration
Effect, D-ribose, L-arginine, taurine, American Ginseng medicinal extract, l-carnitine, L-Ascorbic Acid L-O-Phosphate joint prescription have it is excellent
Gesture, the more than simple addition of several drugs, they, which mutually act synergistically, increases mutual function, to effectively play anti anoxia
Fatigue proof health-care effect.
Specific implementation mode
A kind of Oxygen-deficient endurance fructose powder (liquid) composition is further illustrated the present invention by following specific examples, it is excellent
It can be oral administration solution to select preparation, can also be solid dosage forms, including solid tablet, solid particle dosage form, effervescent tablet and solid
Powder form, the present embodiment are only to illustrate the present invention, are not the limitation to other dosage forms of the present invention.
It is indicated with prescription compages weight ratio, each main group of a kind of Oxygen-deficient endurance fructose powder (liquid) composition of the present invention
At weight ratio following (gauge used with 6g/1000 vial formulation units, is declared again, said preparation unit should not be constituted to this
The limitation of invention):
American Ginseng medicinal extract 50-200g, L carnitine 200-1000g, D-ribose 300-1000g, L-arginine 50-500g, dimension
Raw element C phosphate magnesium 200-1000g, taurine 100-800g, crystal diabetin 500-5000g, oligofructose 500-5000g, sweet tea
Sweet element 10-50g, potassium sorbate 30-50g, essence 0.6-2g, appropriate citric acid.
It is preferred that a kind of weight ratio of each composition of Oxygen-deficient endurance fructose powder (liquid) composition of the invention is:
American Ginseng medicinal extract 100-200g, L carnitine 500-1000g, D-ribose 400-600g, L-arginine 200-500g, dimension
Raw element C phosphate magnesium 400-600g, taurine 300-600g, crystal diabetin 1000-4000g, oligofructose 1000-4500g,
Honey element 10-50g, potassium sorbate 30-50g, essence 0.6-2g, appropriate citric acid.
Embodiment 1:For the weight ratio for being prepared into each composition of pulvis is (by 6g/1000 bottles):
American Ginseng medicinal extract 100g, L carnitine 500g, D-ribose 400g, L-arginine 300g, vitamin C phosphate magnesium
400g, taurine 300g, crystal diabetin 1500g, oligofructose 2420g, honey element 50g, potassium sorbate 30g, appropriate citric acid.
Preparation flow:Raw material → examination → freezer → mark Huaihe River dispensing → ultraviolet-sterilization → crushing → sieving → centre storage
Deposit tank → automation finished product → gland → sterilizing → secondary package → storage.
Embodiment 2:For the weight ratio for being prepared into each composition of pulvis is (by 8g/1000 bottles):
American Ginseng medicinal extract 150g, L carnitine 600g, D-ribose 600g, L-arginine 400g, vitamin C phosphate magnesium
500g, taurine 400g, crystal diabetin 2500g, oligofructose 2770g, honey element 50g, potassium sorbate 30g, appropriate citric acid.
Preparation flow:Raw material → examination → freezer → mark Huaihe River dispensing → ultraviolet-sterilization → crushing → sieving → centre storage
Deposit tank → automation finished product → gland → sterilizing → secondary package → storage.
Embodiment 3:For the weight ratio for being prepared into each composition of pulvis is (by 10g/1000 bottles):
American Ginseng medicinal extract 150g, L carnitine 600g, D-ribose 600g, L-arginine 400g, vitamin C phosphate magnesium
600g, taurine 400g, crystal diabetin 3600g, oligofructose 3570g, honey element 50g, potassium sorbate 30g, appropriate citric acid.
Preparation flow:Raw material → examination → freezer → mark Huaihe River dispensing → ultraviolet-sterilization → crushing → sieving → centre storage
Deposit tank → automation finished product → gland → sterilizing → secondary package → storage.
Embodiment 4:It is prepared into for the weight ratio of each composition of two kinds of dosage forms of A, B agent i.e. pulvis and oral solution:
Using A, B agent as dosage form, wherein:A agent is liquid preparation;B agent is powder preparation form:(no matter A agent and B agent,
Respectively with 1000 bottles be preparation unit use gauge, wherein A agent by 25ml/ bottles, B agent in terms of 6 grams/bottle):
1, A agent:
American Ginseng medicinal extract 100g, l-carnitine 500g, honey element 35g, potassium sorbate 70g, appropriate citric acid, deionized water
25000ml。
If preparation does not have American Ginseng medicinal extract, American Ginseng crude drug 1000g can be used, adds water retting 1 hour, decoction 2 times, often
Secondary 2 hours, collecting decoction, filtration, filtrate is concentrated, be made relative density be 1.08 concentrate, after cooling be added l-carnitine,
Potassium sorbate is added deionized water to total amount, is stirred evenly between citron acid for adjusting pH value 4.5~5.5, stands 24 hours, filtering,
It is distributed into 30ml bottles, seals, with 115 DEG C of pressure sterilizing 30min.
2, B agent:
D-ribose 400g, L-arginine 300g, L-Ascorbic Acid L-O-Phosphate 400g, taurine 300g, citric acid 110g, knot
Brilliant fructose 2300g, oligofructose 2190g.
D-ribose, L-arginine, L-Ascorbic Acid L-O-Phosphate, taurine, citric acid, crystal diabetin, oligofructose are mixed
It closes, 80 mesh of uniform mistake sieves 5 times, and the raw material that mixing is sieved under ultraviolet light be kept in dark place by sterilization packaging, sealing.
Physical and chemical index:PH value 4.5-5.5, lead (in terms of Ps)≤0.5mg/kg, arsenic (in terms of As)≤0.3mg/kg, food additive
Add agent that should meet the regulation of GB2760.
Microbiological indicator:Total number of bacteria (cfu/ml)≤100, coliform (MPN100ml/)≤6, mould (cfu/ml)
≤ 10, saccharomycete (cfu/ml)≤10, pathogenic bacteria (referring to pathogenic entero becteria and pathogenic coccus) must not detect.
A kind of Oxygen-deficient endurance fructose powder (liquid) composition of the present invention, is indicated with prescription compages weight ratio, composition it is each
In the weight of a composition, former, supplementary product consumption is to be made the amounts of 1000 preparation units as formula ratio, such as to be made 1000
Grain, 1000,1000 bags, 1000 milliliters, the amount of supplementary material used in 1000 bottles etc. calculate formula ratio, be not formulated as a percentage
Amount.
This prescription Oxygen-deficient endurance fructose powder (liquid) composition, can be prepared into according to different additives liquid preparation or
Person's solid pharmaceutical preparation can also be tablet and capsule preparations.In fact this prescription Oxygen-deficient endurance fructose powder (liquid) composition, no matter
Using liquid preparation or solid pharmaceutical preparation, ideal healthcare function, as long as being taken by medium of water, whatsoever agent can get
Type can make the composition give full play to curative effect, so that the crowd under anoxic or fatigue state is obtained physical efficiency faster extensive
It is multiple.
This prescription Oxygen-deficient endurance fructose powder (liquid) composition, preferred formulation can be oral administration solution, can also be solid
Dosage form, including solid tablet, solid particle dosage form, effervescent tablet and solid powder dosage form, the present embodiment are only to illustrate the present invention,
It is not the limitation to other dosage forms of the present invention.
This prescription selects D-ribose, L-arginine, taurine, American Ginseng medicinal extract, l-carnitine, vitamin C phosphate magnesium to make
For functional component, and reasonable efficient combination ratio is selected by testing sieve, prescription effect of this prescription is made to generate synergistic effect, from
And the fatigue proof health-care effect of anti anoxia is effectively played, it helps body to regain the enough energy needed for vital movement, restores
The due vigor of body.
Claims (4)
1. a kind of Oxygen-deficient endurance fructose powder (liquid) composition, it is characterised in that:With weight ratio meter, the Oxygen-deficient endurance fructose powder
(liquid) composition main component includes American Ginseng medicinal extract 50-200g, L carnitine 200-1000g, D-ribose 300-1000g, L- essence ammonia
Sour 50-500g, L-Ascorbic Acid L-O-Phosphate 200-1000g, taurine 100-800g, crystal diabetin 500-5000g, oligofructose
500-5000g and corrigent.
2. a kind of preparation method of Oxygen-deficient endurance fructose powder (liquid) composition according to claim 1 is:It is prepared into
Method when pulvis is:American Ginseng medicinal extract 100g, L carnitine 500g, D-ribose 400g, L-arginine 300g, vitamin C phosphoric ester
Magnesium 400g, taurine 300g, crystal diabetin 1500g, oligofructose 2420g, honey element 50g, potassium sorbate 30g, citric acid are suitable
Amount.Preparation flow:Raw material → examination → freezer → mark Huaihe River dispensing → ultraviolet-sterilization → crushing → sieving → intermediate storage tank
→ automation finished product → gland → sterilizing → secondary package → storage.
3. a kind of preparation method of Oxygen-deficient endurance fructose powder (liquid) composition according to claim 1 is:It is prepared into
Oral solution and the method for two kinds of dosage forms of solid powder are:Using A, B agent as dosage form, wherein:A agent is liquid preparation, and B agent is powder
Agent formulation form:A, A agent:American Ginseng medicinal extract 100g, l-carnitine 500g, honey element 35g, potassium sorbate 30g, appropriate citric acid,
The above raw material is mixed and is filtered by deionized water 25000ml, l-carnitine, potassium sorbate is then added, with citron acid for adjusting pH value
Between 4.5~5.5, add deionized water to total amount, stir evenly, stand 24 hours, filtering is distributed into 30ml bottles, is sealed, with 115
DEG C pressure sterilizing 30min.B, B agent:D-ribose 400g, L-arginine 300g, L-Ascorbic Acid L-O-Phosphate 400g, taurine
300g, citric acid 110g, crystal diabetin 2300g, oligofructose 2190g.The above raw material is mixed, 80 mesh of uniform mistake sieves 5 times, will
Mixing the raw material being sieved, sterilization filling is packed under ultraviolet light, and sealing is kept in dark place.
4. a kind of Oxygen-deficient endurance fructose powder (liquid) composition according to claim 1,2,3, it is characterised in that:The present invention
Preferred formulation can be oral administration solution, can also be solid dosage forms, including solid tablet, solid particle, solid powder dosage form,
It is only to illustrate the present invention in the embodiment of the present invention, is not the limitation to other dosage forms of the present invention.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711083908.3A CN108433106A (en) | 2017-11-07 | 2017-11-07 | A kind of Oxygen-deficient endurance fructose powder (liquid) composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711083908.3A CN108433106A (en) | 2017-11-07 | 2017-11-07 | A kind of Oxygen-deficient endurance fructose powder (liquid) composition |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108433106A true CN108433106A (en) | 2018-08-24 |
Family
ID=63190588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711083908.3A Pending CN108433106A (en) | 2017-11-07 | 2017-11-07 | A kind of Oxygen-deficient endurance fructose powder (liquid) composition |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108433106A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT202100011084A1 (en) * | 2021-04-30 | 2022-10-30 | Pharmanutra S P A | NUTRACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF CHRONIC FATIGUE/FATIGUE POST COVID-19 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6159942A (en) * | 1998-06-19 | 2000-12-12 | Bioenergy, Inc. | Compositions for increasing energy in vivo |
CN101356972A (en) * | 2007-07-30 | 2009-02-04 | 石药集团中奇制药技术(石家庄)有限公司 | Anti-fatigue anti-hypoxia sports health food |
CN103211141A (en) * | 2012-10-19 | 2013-07-24 | 莫海仪 | Application of anti-hypoxia and anti-fatigue oral composition in health product |
-
2017
- 2017-11-07 CN CN201711083908.3A patent/CN108433106A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6159942A (en) * | 1998-06-19 | 2000-12-12 | Bioenergy, Inc. | Compositions for increasing energy in vivo |
CN101356972A (en) * | 2007-07-30 | 2009-02-04 | 石药集团中奇制药技术(石家庄)有限公司 | Anti-fatigue anti-hypoxia sports health food |
CN103211141A (en) * | 2012-10-19 | 2013-07-24 | 莫海仪 | Application of anti-hypoxia and anti-fatigue oral composition in health product |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT202100011084A1 (en) * | 2021-04-30 | 2022-10-30 | Pharmanutra S P A | NUTRACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF CHRONIC FATIGUE/FATIGUE POST COVID-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8778410B2 (en) | Oral or enteral composition useful for recovery of physical functions | |
US10485836B2 (en) | Anti-fatigue composition used for increasing endurance performance, and use of the same | |
CN105899213A (en) | Uses of oxygenated cholesterol sulfates (ocs) | |
CN101347422B (en) | Uses of salvianolic acid A in preventing and/or treating diabetes and complication | |
CN103006730A (en) | Composition containing arginine and panax notoginseng extract for promoting nitric oxide generation and preventing and protecting cardiovascular disease | |
CN105707637A (en) | Solid beverage capable of reduce blood glucose, and preparation method thereof | |
CN104489681A (en) | Composition with function of enhancing immunity, health product and preparation method thereof | |
CN103211141A (en) | Application of anti-hypoxia and anti-fatigue oral composition in health product | |
CN109528904A (en) | A kind of kidney-tonifying health-care, boosting qi and nourishing yin, pharmaceutical composition of high-content ginsenoside and preparation method thereof | |
CN103007098B (en) | Composition with functions of accelerating generation of nitric oxide and improving immunity and containing arginine, ginseng and coix seeds | |
CN101564378A (en) | Levocarnitine oral solution and preparation method thereof | |
US9931367B2 (en) | Uses of cistanche tubulosa extract and isoacteoside in protecting muscle | |
CN100998610A (en) | Antifatigue medicine contg. ombrophyte red chlorella | |
CN108433106A (en) | A kind of Oxygen-deficient endurance fructose powder (liquid) composition | |
CN103202506B (en) | One produces refreshing effect to the mind plant beverage and production method thereof | |
US20050153020A1 (en) | Composition comprising phosphate | |
CN101317665A (en) | Alkalescent high-energy agent for health and long life of human | |
CN110664824B (en) | Nutrition supporting agent and preparation method and application thereof | |
CN103478703A (en) | Health food with fatigue resistance function and preparation method thereof | |
CN100391476C (en) | Medicine composition for delaying senility and raising immunity and its prepn | |
CN100408047C (en) | Medicinal composition of fructose diphosphate sodium and magnesium salt | |
CN110522028A (en) | A kind of composition that protect liver is antifatigue and its application | |
CN104225228A (en) | Traditional Chinese medicine preparation for regulating blood sugar | |
US20230111558A1 (en) | Composition for Preventing and Treating Heart Dysfunction and its Application Thereof | |
CN108272084A (en) | It is a kind of prevent thermoplegia composition and its application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Li Jifeng Document name: Notification to Make Rectification |
|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180824 |